Conducting clinical research studies with
SKILL, KNOWLEDGE and SAFETY.
Call to participate
860.443.4567

Posts Tagged ‘ Hypoactive Sexual Desire Disorder ’

Decreased Desire Study Update

Monday, November 7th, 2016

Research volunteers truly do make a difference in this world.  It has been announced The Reconnect Studies, investigating bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD) has met the pre-specified co-primary efficacy endpoints in both Phase 3 clinical trials.

Palatin is developing bremelanotide as a subcutaneous, on-demand, as needed treatment for women who have not yet experienced menopause and have been diagnosed with HSDD.

“It was reported women using bremelanotide had clinically meaningful and statistically significant improvements in their desire and associated distress which are the defining clinical issues for an HSDD diagnosis,” said Carl Spana, Ph.D., President and CEO of Palatin.  He continued, “I am especially grateful to all of the women who volunteered to be a part of these studies.”

The CCRstudies team wishes to thank those women who came forward to participate in The Reconnect Study here in New London.  Dr. Robert Spitz served as the Primary Investigator of the study conducted at Coastal Connecticut Research, and Jessie Jellison Hatfield, LPN served as Study Coordinator.  We are truly grateful for all those who continually come forward to participate in research!

If you wish to learn more about becoming a volunteer for current or future studies are welcome to contact us today at (860)443-4567.